![]() ![]() Trail participants (normally from developing countries/undeveloped countries) may not benefit from trail results. ![]() O Study design with multiple primary goals.Ģ.Ğthical disturbance. O Regulatory bodies and drug companies are encouraged to share their clinical data to the public, for not only surveillance but also better decision-making for doctors. OĚll trails should be registered, and publish its results no matter of positive or negative. OĚuthor recommends to use systemic review for better evaluate clinical trial results, which enhance further decision making. For those negatively resulted papers, they tend to be withhold by investigators and drug companies, or refused to be published by major journals. Industry funded trails were more likely to produce positive outcomes. Apart from it, doctors, drug reps, ghost writers, and regulatory bodies all have involved to worsen the situation and make the evidence-based clinical research more miserable.ġ.ěiased trails. Pharmaceutical industry play a tremendous influence on data integrity and transparency, they normally refuse to disclose. The major concern raised from BP was on missing reliable data on academic papers. ![]()
0 Comments
Leave a Reply. |